# A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies

> **NCT01080664** · PHASE1 · TERMINATED · sponsor: **EMD Serono** · enrollment: 124 (actual)

## Conditions studied

- Haematological Malignancies

## Interventions

- **DRUG:** AS703569
- **DRUG:** AS703569

## Key facts

- **NCT ID:** NCT01080664
- **Lead sponsor:** EMD Serono
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-12
- **Primary completion:** 2010-03
- **Final completion:** 2011-08
- **Target enrollment:** 124 (ACTUAL)
- **Why stopped:** Please see Purpose Statement below
- **Last updated:** 2013-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01080664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01080664, "A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01080664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*